PATENT CLAIM ANALYSIS

Application Number: 16181161
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-04
Patent Classification: ["514", "561000"]

Abstract:
A method of treating an ocular disorder in a subject includes administering to the subject subtherapeutic amounts of two or more agents that inhibit and/or blocks the activation of Gs- or Gq-protein coupled receptors or Gs- or Gq-signaling cascade in ocular cells of the subject, and/or activates Gi-protein coupled receptors, which is induced or triggered by light induced all-trans-retinal generation.

Claim (Index 5):
The method of  claim 1 , wherein the agents comprise bromocriptine, metoprolol, and tamsulosin.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 98.0
- Lexical Diversity: 1.43182
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15487963', '14262141', '15316412', '15315207', '15529299']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8244200901484805
- 35 USC 102 Novelty (BERT): 0.7252035602503976
- Combined Prediction Score: 0.8144984371586723
- Mean Citation Score: 491.614114
- Max Citation Score: 832.2386
- Similarity Product: 774.7957282767417

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test